PRODUCT OVERVIEW & COMPOSITION
Brand / Manufacturer: Bioniche Pharma
Active Ingredient: Stanozolol USP (10 mg per tablet)
Pharmacological Class: Synthetic Anabolic-Androgenic Steroid ($17\alpha$-alkylated Dihydrotestosterone derivative)
Bioniche Pharma Stanozolol is an orally active anabolic agent featuring a unique pyrazole ring attached to the steroid nucleus. Engineered by Bioniche Pharma to optimize anabolic stimulation while reducing androgenic activity, it promotes tissue synthesis, cellular nitrogen retention, and structural protein accumulation.
CLINICAL PHARMACOLOGY & METABOLISM
As a modified derivative of dihydrotestosterone, Bioniche Pharma Stanozolol binds with target androgen receptors to stimulate anabolic processes. Clinically, Stanozolol preparations from Bioniche Pharma markedly alter serum lipid profiles by inducing elevations in low-density lipoproteins (LDL) and significant reductions in high-density lipoproteins (HDL). Additionally, it modulates specific hepatic protein synthesis, including the upregulation of C1 esterase inhibitor levels.
INDICATIONS & CLINICAL USE
- Prophylactic management of hereditary angioedema (HAE) to reduce the frequency, duration, and severity of acute cutaneous and mucosal swelling attacks using Bioniche Pharma formulations.
- Therapeutic support in conditions requiring enhanced protein synthesis and nitrogen conservation under strict Bioniche Pharma medical supervision.
CONTRAINDICATIONS
- Male patients with confirmed or suspected carcinoma of the prostate gland or male breast cancer.
- Female breast carcinoma complicated by hypercalcemia, as androgenic anabolic agents can accelerate osteolytic bone resorption.
- Nephrosis or the nephrotic phase of chronic nephritis.
- Pregnancy and lactation due to risks of fetal virilization and endocrine disruption.
- Patients with known hypersensitivity to Bioniche Pharma Stanozolol or any inactive tablet components in the Bioniche Pharma formulation.
PRECAUTIONS & HEMATOLOGICAL MONITORS
- Coagulation Factor Suppression: Anabolic steroids can suppress hepatic synthesis of clotting factors II, V, VII, and X, leading to prolonged prothrombin time (PT/INR) and an increased propensity for bleeding during Bioniche Pharma therapy.
- Lipid & Hepatic Surveillance: Routine monitoring of serum lipid panels and hepatic enzymes is strongly advised during Bioniche Pharma Stanozolol therapy due to $17\alpha$-alkylated metabolic strain.
DRUG INTERACTIONS
- Oral Anticoagulants: Co-administration of Bioniche Pharma Stanozolol with coumarin derivatives or other oral anticoagulants significantly increases sensitivity and bleeding risk. Anticoagulant dosage reduction and regular prothrombin time monitoring may be required to maintain safe therapeutic levels.
ADVERSE REACTIONS & HEPATIC WARNINGS
- Hepatic Toxicity: Cholestatic jaundice, elevated transaminases, and in rare severe instances, hepatic necrosis associated with Bioniche Pharma administration. Extended or high-dose administration carries risks of peliosis hepatis and hepatocellular neoplasms.
- Cardiovascular & Metabolic: Marked suppression of HDL cholesterol alongside increased LDL cholesterol, increasing cardiovascular stress during prolonged courses of Bioniche Pharma therapy.
- Dermatological & Androgenic: Acne vulgaris, oily skin, and potential virilization signs in sensitive or female patients receiving Bioniche Pharma Stanozolol.
DOSAGE & ADMINISTRATION
Dosing regimens for Bioniche Pharma Stanozolol must be individually determined and strictly supervised by a qualified physician, taking into consideration clinical indications, serum lipid profiles, and diagnostic laboratory monitoring.
STORAGE & HANDLING
Store Bioniche Pharma products in a cool, dry place away from direct light exposure, heat, and moisture. Keep strictly out of reach and sight of children.